Literature DB >> 18457652

Inhibition of serine proteases by a new class of cyclosulfamide-based carbamylating agents.

Qingliang Yang1, Yi Li, Dengfeng Dou, Xiangdong Gan, Swathi Mohan, Christopher S Groutas, Laura E Stevenson, Zhong Lai, Kevin R Alliston, Jiaying Zhong, Todd D Williams, William C Groutas.   

Abstract

A new class of carbamylating agents based on the cyclosulfamide scaffold is reported. These compounds were found to be efficient time-dependent inhibitors of human neutrophil elastase (HNE). Exploitation of the three sites of diversity present in the cyclosulfamide scaffold yielded compounds which inhibited HNE but not proteinase 3 (PR 3) or bovine trypsin. The findings reported herein suggest that the introduction of appropriate recognition elements into the cyclosulfamide scaffold may lead to highly selective agents of potential value in the design of activity-based probes suitable for investigating proteases associated with the pathogenesis of chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18457652      PMCID: PMC2492831          DOI: 10.1016/j.abb.2008.04.020

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  29 in total

Review 1.  Pathogenesis of chronic obstructive pulmonary disease.

Authors:  William MacNee
Journal:  Proc Am Thorac Soc       Date:  2005

Review 2.  Mechanism-based profiling of enzyme families.

Authors:  Michael J Evans; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2006-08       Impact factor: 60.622

3.  Influence of charge distribution at the active site surface on the substrate specificity of human neutrophil protease 3 and elastase. A kinetic and molecular modeling analysis.

Authors:  Brice Korkmaz; Eric Hajjar; Timofey Kalupov; Nathalie Reuter; Michèle Brillard-Bourdet; Thierry Moreau; Luiz Juliano; Francis Gauthier
Journal:  J Biol Chem       Date:  2006-11-06       Impact factor: 5.157

4.  A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases.

Authors:  Weiwei Li; Jacqueline L Blankman; Benjamin F Cravatt
Journal:  J Am Chem Soc       Date:  2007-07-13       Impact factor: 15.419

Review 5.  COPD: current therapeutic interventions and future approaches.

Authors:  P J Barnes; R A Stockley
Journal:  Eur Respir J       Date:  2005-06       Impact factor: 16.671

Review 6.  Chronic obstructive pulmonary disease: the disease and its burden to society.

Authors:  David M G Halpin; Marc Miravitlles
Journal:  Proc Am Thorac Soc       Date:  2006-09

Review 7.  New molecular targets for the treatment of neutrophilic diseases.

Authors:  Peter J Barnes
Journal:  J Allergy Clin Immunol       Date:  2007-03-13       Impact factor: 10.793

Review 8.  Pathogenesis of chronic obstructive pulmonary disease.

Authors:  William Macnee
Journal:  Clin Chest Med       Date:  2007-09       Impact factor: 2.878

9.  Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease.

Authors:  Toshinori Yoshida; Rubin M Tuder
Journal:  Physiol Rev       Date:  2007-07       Impact factor: 37.312

10.  Development of activity-based probes for trypsin-family serine proteases.

Authors:  Zhengying Pan; Douglas A Jeffery; Kareem Chehade; Jerlyn Beltman; James M Clark; Paul Grothaus; Matthew Bogyo; Amos Baruch
Journal:  Bioorg Med Chem Lett       Date:  2006-03-22       Impact factor: 2.823

View more
  3 in total

Review 1.  Neutrophil elastase inhibitors.

Authors:  William C Groutas; Dengfeng Dou; Kevin R Alliston
Journal:  Expert Opin Ther Pat       Date:  2011-01-16       Impact factor: 6.674

2.  Catalytic asymmetric synthesis of cyclic sulfamides from conjugated dienes.

Authors:  Richard G Cornwall; Baoguo Zhao; Yian Shi
Journal:  Org Lett       Date:  2013-01-30       Impact factor: 6.005

3.  Intramolecular 1,5-C(sp3)-H Radical Amination via Co(II)-Based Metalloradical Catalysis for Five-Membered Cyclic Sulfamides.

Authors:  Hongjian Lu; Kai Lang; Huiling Jiang; Lukasz Wojtas; X Peter Zhang
Journal:  Chem Sci       Date:  2016-07-28       Impact factor: 9.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.